Intensive high-dose chemotherapy with peripheral blood progenitor cell (PBPC) transplantation is a common strategy for aggressive non-Hodgkin's lymphomas (NHL). A retrospective cost-effectiveness analysis of CD34 ؉ cell dose was carried out. Between 1994 and 1998, 28 patients were included. Efficacy was measured by the length of aplasia. Data collection concerned the period from graft day until discharge from hospital, and the post-graft period until graft day ؉100. Patients transplanted using a cell dose greater than 5 ؋ 10 
Therefore, resource allocation should be optimized. The graft progenitor cell content appears to be the major factor predicting granulocyte and platelet recovery. [13] [14] [15] [16] [17] Recently, two studies (not published) including solid tumors and hematological malignancies, showed that implementing optimal progenitor content would reduce resource consumption for PBPC patients. 18, 19 Here, retrospective costeffectiveness analysis of CD34 + cell dose was carried out in aggressive non-Hodgkin's lymphomas, from the hospital perspective.
Materials and methods

Patients
Consecutive patients treated in the Besançon University Hospital hematology ward with HDC followed by PBPCT for aggressive NHL between 1994 and 1998 were included, independently of inclusion in a randomized trial. Doublegraft procedure patients were excluded. For patients with two independent transplantations during this period, only the first graft was studied. Those previously treated with bone marrow transplantation (autologous or allogeneic) were also excluded.
Data
Clinical and biological data were collected from the medical records of each patient. The measurement of progenitor cell content was performed by CD34
+ cell enumeration and CFU-GM assay as follows.
Cell counting and viability tests: Nucleated cells were determined with an automatic cell counter (STKS, Coultronics, Margency, France). Viability was determined by trypan blue exclusion.
Flow cytometry for CD34
+ cell quantification: A quantity of 1 × 10 6 cells were stained with a combination of PEconjugated anti-CD34 (HPCA-2, clone 8G12) and FITCconjugated anti-CD45 (Hlc-1, clone 2D1) (Becton Dickinson, Le Pont-de-Claix, France). Isotype PE and FITC controls were performed at the same time. All samples were treated with a lysing solution. A minimum of 50 000 gating events was analyzed for each sample, using a FACSCalibur flow cytometer (Becton Dickinson). The events were gated into a region (R1) on a fluorescence (FL1) vs side scatter (SS) dot plot to exclude CD45 + events. The percentage of CD34 + events in cell suspension was calculated in R1 as the percentage of CD45 + events with low SS on an FL2 vs SS dot plot.
Clonogeneic assays: For CFU-GM assays, 4 × 10 4 cells/ml were plated in duplicate in 0.3% (w/v) agar in Iscove's medium (Gibco, Cergy Pontoise, France) supplemented with 20% (v/v) heat-inactivated FCS, 2 ng/ml Interleukin-3 (RD Systems, Abingdon, UK), 5 ng/ml GM-CSF (RD Systems), human placental conditioned medium (8%, home made). Cultures were incubated at 37°C in a fully humidified atmosphere with 5% CO 2 in air for 12 days. Clusters of 20 to 50 cells and colonies of 50 or more cells were scored using an inverted microscope.
Supportive care
During the transplant and post-transplant periods, platelet were transfused when the platelet count was less than 20 × 10 9 /l or in cases of bleeding with low platelet counts. Packed red blood cells were transfused to maintain a hemoglobin level higher than 8 g/dl. All blood components were leukocyte-reduced and irradiated and red blood cells were phenotyped. Broad-spectrum i.v. antibiotics were given in cases of temperature у38°C and modified according to current practice for neutropenia. No growth factor was systematically prescribed post transplantation.
Patients were discharged when the absolute neutrophil count reached at least 0.5 × 10 9 /l, and if they were without progressive complications.
Evaluation criteria
Efficacy was measured by the length of aplasia. The day of neutrophil recovery was defined as the first day with a count greater than 0.5 × 10 9 /l (stable values for at least 2 days). Platelet engraftment was defined as a count of at least 20 × 10 9 /l that was sustained without transfusion for 7 or more days.
For the analysis, two groups of patients were established according to progenitor cell content: less vs more than 5 × 10 6 CD34 + cells/kg. Several studies showed that 5 × 10 6 CD34 + /kg was an optimal count for PBPC transplantation. 17, 20, 21 Economic assessment Data collection concerned the period from graft day until discharge from hospital, as well as the post-graft period until graft day +100. Conditioning regimen costs (hospitalization and treatment), independent of progenitor cell count, were excluded. 22 The analysis was performed from the point of view of the Hospital Institution.
Resources used and direct medical costs were identified for each patient, including: (1) hospitalization, (2) drugs (anti-infectious agents (antibiotics, antiviral and antifungal agents), hematopoietic growth factors (HGF)), (3) blood products. These parameters corresponded to more than 90% of the total transplantation cost. [8] [9] [10] Unit prices of hospitalization were obtained from the analytic accounting system of the Besançon University Hospital (1997). 23 These charges included non-medical and medical costs such as medical and non-medical personnel, hospital structure costs (eg overheads, financial expenses), logistic costs (eg hotel, laundry, food), small equipment, and medical costs (eg medication, medical devices, radiology and biology). The per diem costs that were used, except the variable direct medical costs, were obtained from the clinical record of each patient ( Table 1) .
The official tariff for blood products as published in the 'Journal Officiel' on 28 December 1997 and applied during 1998 was used. 24 Unit prices of drugs (anti-infectious agents and hematopoietic growth factors) were obtained from wholesale price lists applied in the Besançon Hospital Pharmacy in 1998.
Monetary values for 1998 French prices were used for all components. The exchange rate used was US$ 1 = 5 French francs.
Statistical analysis
Comparison of efficacy (length of neutropenia and thrombopenia) and costs were achieved between two groups of progenitor cell content. Only harvests that were actually re-infused were considered for the analyses.
Differences in mean values of clinical results (aplasia, number of days of hospitalization, number of platelet and red blood cell units transfused, number of days of i.v. antiinfectious agents) were tested using a non-parametric Mann-Whitney test. Correlation between CD34
+ and CFU-GM counts was explored using the Pearson coefficient. These analyses were performed with BMDP Statistical Software (␣ = 0.05, ␤ = 0.1). 25 Data are expressed in each group as a mean ± s.d, except where mentioned in Tables. Table 1 Unit prices (US$) 
Type Unit prices (US$)
Results
Patients
Between 1994 and 1998, 28 patients were included. Average age and sex ratio were respectively 42 years (19-64) and 2.1 (19 male/9 female). All patients had received previous conventional chemotherapy before HDC. Seventeen patients were included in randomized trials. They were treated chronologically according to GOELAM 71 and GOELAM 72 protocols (GOELAMS: Groupe Ouest Est d'É tude des Leucémies et Autres Maladies du Sang). 28, 29 Three patients with mantle zone lymphomas were treated with VAD (vincristine 0.4 mg/day days 1-4, doxorubicin 9 mg/m 2 /day days 1-4, dexamethasone 20 mg/day days 1-4) plus chloraminophen, according to the phase II study. In 26 cases, HDC was performed as first-line therapy (18 first partial remissions, eight first complete remissions); the average interval between diagnosis and HDC was 5 months (2-10). Two patients were autografted in second complete response after salvage therapy, 10 and 60 months after primary diagnosis respectively. Patient characteristics are summarized in Table 2 . 
Peripheral blood progenitor cells
PBPC were mobilized with conventional chemotherapy, followed by HGF administration at a dose of 5 g/kg (17 G-CSF, 11 GM-CSF). PBPC collection data are listed in Table 3 .
There was a good correlation between the collected number of CD34 + cells and CFU-GM (r = 0.74; P Ͻ 0.001). Therefore, only the CD34 + cell content was used for the analysis.
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Hematopoietic engraftment
After HDC, engraftment was achieved in less than 21 days in 24 patients. No graft failure was observed. Data on engraftment kinetics are listed in Table 4 and Figure 1 . 
Economic assessment
The average length of post-graft hospitalization was only reduced by 1 day with grafts containing more than 5 × 10 6
CD34
+ cells/kg. In this group, discharge was delayed for hematopoietic engraftment for two patients because of infectious complications (one hypoxemic pneumonia and one maxillary sinusitis) ( Table 5 ). After discharge, two patients in each group were re-admitted until day +100: bleeding (one subdural hematoma and one hematuria) in the first group (Ͻ5 × 10 Economic data are summarized in Table 6 . Hospitalization was the major cost factor: 76 to 93% of total cost. A large reduction in procedure cost was obtained with a CD34
+ cell count higher than 5 × 10 6 /kg (−US$2740, −11%). This difference was directly related to the hospitalization (−US$860) and platelet units transfused (−US$1,340). 
Sensitivity analysis
To offset the savings, the length of hospitalization had to be 3 days longer in the second group (more than 5 × 10 6 CD34 + cells/kg) than in the first (less than 5 × 10 6 CD34 + cells/kg). In the same way, reverse results were obtained if the average number of platelet units transfused was multiplied by three in the second group, or negative in the first group.
These sensitivity analyses showed the robustness of our results. For two patients in the second group (more than 5 × 10 6 CD34 + cells/kg), the length of hospitalization was longer than aplasia (+11 and +19 days). A second analysis was performed without these patients. The cost saving obtained with a graft containing at least 5 × 10 6 CD34 + /kg was also US$4000 per patient.
Discussion
Recently, the effect of cell dose on resource utilization in patients undergoing transplant with peripheral blood progenitor cells was reported in two studies. 18, 19 Patients with different malignancies were included in randomized trials. Length of hospitalization and numbers of platelet and red blood cells transfused were studied until discharge or day +30. Our study was performed on a single disease, nonHodgkin's lymphoma. Although this analysis was based on a small number of patients, it had the advantage of using a non-selected population (among the 28 patients, 17 were included in different trials). The results also reflected pragmatic daily medical practice, instead of economic analyses based on a clinical trial. In addition to hospitalization and transfusions, anti-infectious agents, HGF post-graft requirements and additional hospital stays were studied, until day +100.
Among the four patients whose length of neutropenia and/or thrombopenia was longer than 21 days, the CD34 + cell content was lower than 5 × 10 6 /kg in three cases. There was no graft failure, but progenitor cell content was at least 2 × 10 6 CD34 + /kg for all patients. In several studies, failures were observed with less than 1 or 2 × 10 6 progenitors per kg. 34, 35 Patients transplanted using a cell dose greater than 5 × 10 6 /kg were found to have a significant decrease after 6 days in platelet recovery to у20 × 10 9 /l (P Ͻ 0.001). The duration of neutropenia was also shorter (−3 days) in the same group (NS). In many studies, a comparison of engraftment kinetics in step with CD34
+ cell dose has been made (Ͻ5 × 10 6 /kg vs Ͼ5 × 10 6 /kg), including solid tumors and hematological malignancies. For neutropenia, Diaz 21 and Pecora 36 have reported a reduction of 2 days (11 vs 9 days; 10.6 vs 8.6 days). In another study, the difference was just 1 day (11 vs 10 days). 20 Weaver made a similar analysis, of three groups of CD34 + cell content (less than 5, 5 to 10 and more than 10 × 10 6 /kg): the difference was significant (10.5 vs 9.5 vs 9 days).
14 In these studies, platelet engraftment was also compared. With a progenitor cell content higher than 5 × 10 6 /kg, the length of thrombocytopenia was reduced by 8 days (14.9 vs 22.6 days), 21 and 12 days (21 vs 9 days). 20 In Weaver's study, a reduction of 1 day was reported (11.5 vs 10 vs 9 days).
14 Although the number of patients was limited in this present study, a CD34 + cell number greater than 5 × 10 6 /kg also appeared to be a major factor predicting granulocyte and platelet recovery in NHL, according to the other studies. Recently, Ketterer has shown the potential efficiency of re-infusion of more than 15 × 10 6 /kg progenitors. 37 Several studies have shown that hospitalization was the major cost factor in PBPC transplantation. [7] [8] [9] [10] [11] In the present study, this part was more than 70% of total cost. A comparison of three progenitor contents (less than 2.5, 2.5 to 15 and more than 15 × 10 6 CD34 + /kg) showed a significant difference in hospitalization (17 vs 14 vs 13 days) . 37 When a cut-off point of 5 × 10 6 /kg was chosen, the length of hospitalization was reduced with the higher progenitor number (18.5 vs 20.2 and 11 vs 14 days). 18, 19 The cost savings were respectively US$3315 and US$6570. In our study, the difference was only 1 day (17.7 vs 18.7 days); the cost saving was also US$860. Sensitivity analyses showed that this slight reduction was principally related to two patients.
PBPC with a cell dose higher than 5 x 10 6 /kg resulted in reduced transfusion costs (−US$1400). This cost saving was principally related to a significant reduction of platelet transfusion requirements (−US$1340). Ketterer showed that the number of platelet units transfused was dependent on progenitor cell content (Ͻ2.5; 2.5 to 15; and Ͼ15 × 10 6 /kg): 3 vs 2 vs 1 units. 37 Similar results were reported in another study. 20 In two economic studies (Ͻ5 vs Ͼ5 × 10 6 /kg), platelet cost savings were respectively of US$600 and US$1250. 18, 19 The influence of cell dose on other cost factors, ie red blood cells, anti-infectious agents and HGF post-graft, was limited but there was a trend towards more than 5 × 10 6 /kg. A total cost saving of US$2800 was obtained until day +100 in patients transplanted with more than 5 × 10 6 CD34 + cells per kg. Larger cost savings have been reported in previous economic studies, of US$3900 and US$8200 respectively. 18, 19 These differences could be explained by the fact that larger hospitalization reductions (1.7 and 3 days) were identified, and hospitalization unit costs were higher (US$2000 vs US$980 in our study). Despite two extreme values (22 and 31 days) of hospitalization in the second group (Ͼ5 × 10 6 CD34 + /kg), sensitivity analysis showed the robustness of our results, which were only reversed by extreme or improbable values.
The timing of harvest could be optimized by a CD34 + concentration measurement in peripheral blood. 38 Poor risk mobilization factors need to be well identified and taken into consideration to optimize harvesting. 13, 39 The consequences would be a harvest that takes place as early as possible, and/or the use of other strategies for the hard-tomobilize patients as described by Stiff. These strategies will need to be evaluated for their economic consequences. 40 A previous study showed that post-transplant neutropenia could be markedly reduced (even abrogated for some patients) by the infusion of ex vivo expanded CD34 + cells. 41 In conclusion, our results showed that a CD34 + cell dose higher than 5 × 10 6 /kg was more cost-effective than a lower dose in non-Hodgkin's lymphoma patients. In agreement with other studies, this dose led to increased hematopoietic engraftment. Consequently, significant cost savings could be obtained. These findings should be confirmed in NHL by
Bone Marrow Transplantation a multicenter study, including a large number of patients. Nevertheless, the collection of a minimal number of 5 × 10 6 /kg CD34 + cells would appear to be necessary.
